Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;10(3):61-67.
doi: 10.1177/1759720X17752037. Epub 2018 Jan 11.

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis

Delilah McCarty  1 , April Robinson  2
Affiliations
Review

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis

Delilah McCarty et al. Ther Adv Musculoskelet Dis. 2018 Mar.

Abstract

The mainstay of rheumatoid arthritis (RA) treatment involves the use of medications that slow disease progression and reduce inflammation. Inadequate treatment responses and intolerances to conventional RA treatment have led to the development of biologic agents for the management of moderate-to-severe disease activity. Interleukin-6 (IL-6) inhibition is one of the targets for biologic activity in RA treatment. IL-6 is found in excess in the synovial fluid and contributes to joint erosion through its action on osteoclast cells. Sarilumab is a new IL-6 inhibitor indicated for the treatment of moderate-to-severe RA as monotherapy or in combination with conventional therapies in patients with an inadequate response to previous RA treatment.

Keywords: Rheumatoid arthritis; biologic DMARD; interleukin-6; sarilumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Delilah McCarty is currently employed by Novo Nordisk, Inc as an obesity medical liaison. There is no conflict of interest to declare between employment and this manuscript. Author April Robinson declares no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Helmick CG, Felson DT, Lawrence RC, et al. Estimate of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008; 58: 15–25. - PubMed
    1. Singh JA, Saag KG, Bridges SL, Jr, et al. 2015 American College of Rheumatology guidelines for the treatment of rheumatoid arthritis. Arthritis Care Res 2016; 68: 1–25. - PubMed
    1. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirhuematic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960–977. - PubMed
    1. Regeneron Pharmaceuticals, Inc. Regeneron and Sanofi announce FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients, http://investor.regeneron.com/releaseDetail.cfm?releaseid=1027419 (2017, accessed 16 September 2017).
    1. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295. - PMC - PubMed

LinkOut - more resources